Distress and quality of life in autologous stem cell transplantation: stepped care.

Completed

• Conditions: hematological malignancy; autologous stem cell transplantation; acute leukemia; multiple myeloma; (non-)Hodgkin; anxiety; depressionhematologische maligniteit; autologe stamceltransplantatie; acute leukemie; multipel myeloom

• Registration Number: NL-OMON28586
• Lead Sponsor: Inholland University, Research Group Mental Health Nursing, Amsterdam, the NetherlandsVU University Medical Center, Amsterdam, the Netherlands

Brief Summary

/A

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 28 February 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 128

Inclusion Criteria

1. Patients with hematological malignancy (multiple myeloma, (relapsed) (non-)Hodgkin lymphoma, acute myeloid leukemia, or acute lymphoid leukemia) treated with autologous stem cell transplantation following high-dose chemotherapy;

2. Life expectation > 3 months.

Exclusion Criteria

1. Age < 18 or > 65 years (65 is included);

2. Insufficient command of the Dutch language to complete questionnaires; or, if so: no support by family or professional interpreters;

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Psychological distress (measured with the HADS) and physical role function (subscale from the EORTC-QLQ-C30).

Secondary Outcome Measures

Name	Time	Method
Other measures of psychological distress (PHQ-9, STAI-state), other aspects of quality of life (EORTC-QLQ-C30, SF-36), cognitions and coping (DGSS, SPSI-R).